Journal of Assisted Reproduction and Genetics

, Volume 32, Issue 1, pp 91–94 | Cite as

CYP2C19 polymorphism increases the risk of endometriosis

  • Denise Maria Christofolini
  • Aline Amaro
  • Fernanda Mafra
  • Amanda Sonnewend
  • Bianca Bianco
  • Caio Parente Barbosa



Estrogen metabolizing gene mutations can be associated with defective hormonal signaling leading to disease processes. Endometriosis is an estrogen dependent that can be influenced by defective signaling in the estrogen pathway.


To evaluate the association of A/G 85952 CYP2C19 and A/G 937 HSD17B1 gene polymorphisms with endometriosis through the investigation of a large Brazilian sample of women with endometriosis and a fertile control group.


Five hundred women with endometriosis and 500 women without endometriosis were tested for CYP2C19 and HSD17B1 polymorphisms, by TaqMan Real Time PCR. The results were statistically analyzed by chi-square, logistic regression and tested for Hardy-Weinberg equilibrium.


The comparison of genotype and allelic frequency of CYP2C19 polymorphism (rs11592737) in patients with endometriosis and control group showed a statistically significant difference (p = 0.0203) and for the HSD17B1 polymorphism (rs605059) differences were not significant (p = 0.0687). Comparing the stages I/II and III/IV endometriosis with the control group for the CYP2C19 we observed p = 0.0133 and p = 0.0564, respectively, and for HSD17B1 the values for p = 0.4319 and p = 0.0667.


We observed that CYP2C19 polymorphism is associated with endometrisis in Brazilian women and can be considered a potential biomarker of the disease.


Endometriosis CYP2C19 HSD17B1 Infertility Molecular biomarsker 



The authors thank the Brazilian agency Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) for scientific initiation scholarship granted by the graduate student Amanda Sonnewend and scientific grant #470333/2013-8.


  1. 1.
    El-Mahgoub S, Yaseen S. A positive proof for the theory of coelomic metaplasia. Am J Obstet Gynecol. 1980;137:137–40.PubMedGoogle Scholar
  2. 2.
    Giudice LC, Kao LC. Endometriosis. Lancet. 2004;364:1789–99.PubMedCrossRefGoogle Scholar
  3. 3.
    Noble LS, Simpson ER, Johns A, Bulun SE. Aromatase expression in endometriosis. J Clin Endocrinol Metab. 1996;81:174–9.PubMedGoogle Scholar
  4. 4.
    Painter JN, Nyholt DR, Morris A, Zhao ZZ, Henders AK, Lambert A, et al. High-density fine-mapping of a chromosome 10q26 linkage peak suggests association between endometriosis and variants close to CYP2C19. Fertil Steril. 2011;95(7):2236–40.Google Scholar
  5. 5.
    Baranova H, Bothorishvili R, Canis M, Albuisson E, Perriot S, Glowaczower E, et al. Glutathione S-transferase M1 gene polymorfism and susceptibility to endometriosis in a French population. Mol Hum Reprod. 1997;3:775–80.PubMedCrossRefGoogle Scholar
  6. 6.
    Chang CC, Hsieh YY, Tsai FJ, Tsai CH, Tsai HD, Lin CC. The praline form of p53 codon 72 polymorphism is associated with endometriosis. Fertil Steril. 2002;77(1):43–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Kim SH, Choi YM, Choung SH, Jun JK, Kim JG, Moon SY. Vascular endothelial growth factor gene +405 C/G polymorphism is associated with susceptibility to advanced stage endometriosis. Hum Reprod. 2005;20(10):2904–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Hsieh YY, Lin CS. P53 codon 11, 72, and 248 gene polymorphism in endometriosis. Int J Biol Sci. 2006;2(4):188–93.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Lukacik P, Kavanagh KL, Oppermann U. Structure and function of human 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol. 2006;248:61–71.PubMedCrossRefGoogle Scholar
  10. 10.
    Normand T, Narod S, Labrie F, Simard J. Detection of polymorphisms in the estradiol 17β-hydroxysteroid dehydrogenase 2 gene at the EDH17B2 locus on 17q11–q21. Hum Mol Genet. 1993;2:479–83.PubMedCrossRefGoogle Scholar
  11. 11.
    Mannermaa A, Peltoketo H, Winqvist R, Ponder B, Kiviniemi H, Easton D, et al. Human familial and sporadic breast cancer: analysis of the coding regions of the 17β-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay. Hum Genet. 1994;93:319–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Revised American Society for Reproductive Medicine classification of endometriosis; 1996, Fertil Steril. 1997; 67(5):817–821.Google Scholar
  13. 13.
    Lahiri DK, Nurnberger JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19(19):5444.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Bulun SE, Zeitoun KM, Takayama K, Sasano H. Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance. J Mol Endocrinol. 2000;25:35–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Bulun SE, Economos K, Miller D, Simpson ER. CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. J Clin Endocrinol Metab. 1994;79:1831–4.PubMedGoogle Scholar
  16. 16.
    Trabert B, Schwartz SM, Peters U, De Roos AJ, Chen C, Scholes D, et al. Genetic variation in the sex hormone metabolic pathway and endometriosis risk: an evaluation of candidate genes. Fertil Steril. 2011;96(6):1401–6.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, et al. Polymorphisms Associated With Circulating Sex Hormone Levels in Postmenopausal Women. Journal of the National Cancer Institute 2004; 96 (12).Google Scholar
  18. 18.
    Tsuchiya M, Nakao H, Katoh T, Sasaki H, Hiroshima M, Tanaka T, et al. Association between endometriosis and genetics polymorphisms of estradiol-synthesizing enzyme genes HSD17B1 and CYP19. Hum Reprod. 2005;20(4):974–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Cayan F, Ayaz L, Aban M, Dilek S, Gümüş LT. Role of CYP2C19 polymorphisms in patients with endometriosis. Gynecol Endocrinol. 2009;25(8):530–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Bozdag G, Alp A, Saribas Z, Tuncer S, Aksu T, Gurgan T. CYP17 and CYP2C19 gene polymorphisms in patients with endometriosis. Reprod BioMed Online. 2010;20(2):286–90.PubMedCrossRefGoogle Scholar
  21. 21.
    Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I. HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol Biomark Prev. 2004;13:213–9.CrossRefGoogle Scholar
  22. 22.
    Martel C, Rheaume J, Takahashi M, Trudel C, Couet J, Luu-The V, et al. Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. J Steroid Biochem Mol Biol. 1992;41:597–60.PubMedCrossRefGoogle Scholar
  23. 23.
    Messinger J, Husen B, Koskimies P, Hirvela L, Kallio L, Saarenketo P, et al. Estrone C15 derivatives — a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. Mol Cell Endocrinol. 2009;1–2(301):216–24.CrossRefGoogle Scholar
  24. 24.
    Bukulmez O, Hardy DB, Carr BR, Auchus RJ, Toloubeydokhti T, Word RA, et al. Androstenedione up-regulation of endometrial aromatase expression via local conversion to estrogen: potential relevance to the pathogenesis of endometriosis. J Clin Endocrinol Metab. 2008;93(9):3471–7.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Santos RP, Encinas F, Lasmar RB, Granjeiro JM, Penna IA. Polimorfismos nos genes MMP2, MMP13, CYP1A1, GSTM1 e EMX2 e endometriose. Femina. 2011;39(6):316.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Denise Maria Christofolini
    • 1
  • Aline Amaro
    • 2
  • Fernanda Mafra
    • 2
  • Amanda Sonnewend
    • 2
  • Bianca Bianco
    • 2
  • Caio Parente Barbosa
    • 2
  1. 1.Instituto Ideia Fertil de Saúde Reprodutiva, Morphology Department, FMABCSanto AndréBrazil
  2. 2.Instituto Ideia Fertil de Saúde Reprodutiva, Collective Health Department, FMABCSanto AndréBrazil

Personalised recommendations